M. Weinblatt

1.0k total citations
40 papers, 837 citations indexed

About

M. Weinblatt is a scholar working on Rheumatology, Genetics and Immunology. According to data from OpenAlex, M. Weinblatt has authored 40 papers receiving a total of 837 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 18 papers in Genetics and 8 papers in Immunology. Recurrent topics in M. Weinblatt's work include Rheumatoid Arthritis Research and Therapies (24 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Systemic Lupus Erythematosus Research (11 papers). M. Weinblatt is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (24 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Systemic Lupus Erythematosus Research (11 papers). M. Weinblatt collaborates with scholars based in United States, United Kingdom and Canada. M. Weinblatt's co-authors include David H. Solomon, Jerry Avorn, Christine Canning, Sebastian Schneeweiß, J.N. Katz, Nicola Goodson, Soko Setoguchi, Nancy A. Shadick, Jing Cui and Robert J. Glass and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Advances in experimental medicine and biology.

In The Last Decade

M. Weinblatt

38 papers receiving 808 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Weinblatt United States	13	591	188	141	130	124	40	837
Naomi B. Klarenbeek Netherlands	16	716 1.2×	247 1.3×	139 1.0×	161 1.2×	63 0.5×	36	885
C J Edwards United Kingdom	10	539 0.9×	125 0.7×	60 0.4×	197 1.5×	107 0.9×	22	787
Lotta Ljung Sweden	15	937 1.6×	315 1.7×	146 1.0×	255 2.0×	192 1.5×	43	1.3k
K A Grindulis United Kingdom	15	581 1.0×	170 0.9×	74 0.5×	113 0.9×	41 0.3×	25	827
Toru Yoshinari Japan	12	283 0.5×	123 0.7×	116 0.8×	181 1.4×	38 0.3×	20	855
Daniele Compagnone Germany	8	322 0.5×	185 1.0×	58 0.4×	102 0.8×	71 0.6×	11	512
O. Mutru Finland	12	544 0.9×	99 0.5×	56 0.4×	99 0.8×	125 1.0×	14	827
Etsuji Suehisa Japan	18	478 0.8×	629 3.3×	66 0.5×	165 1.3×	142 1.1×	48	1.0k
Mirella Alpa Italy	18	313 0.5×	57 0.3×	160 1.1×	133 1.0×	357 2.9×	28	1.1k
R. Rau Germany	20	1.2k 2.1×	440 2.3×	218 1.5×	200 1.5×	40 0.3×	49	1.5k

Countries citing papers authored by M. Weinblatt

Since Specialization

Citations

This map shows the geographic impact of M. Weinblatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Weinblatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Weinblatt more than expected).

Fields of papers citing papers by M. Weinblatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Weinblatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Weinblatt. The network helps show where M. Weinblatt may publish in the future.

Co-authorship network of co-authors of M. Weinblatt

This figure shows the co-authorship network connecting the top 25 collaborators of M. Weinblatt. A scholar is included among the top collaborators of M. Weinblatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Weinblatt. M. Weinblatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weinblatt, M., et al.. (2018). Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials. Oxford University Research Archive (ORA) (University of Oxford). 2 indexed citations

Emery, Paul, Peter C. Taylor, M. Weinblatt, et al.. (2017). Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study. Oxford University Research Archive (ORA) (University of Oxford). 69. 2 indexed citations

Emery, Paul, M. Weinblatt, D.E. Furst, et al.. (2016). Clinical Responses and Improvements in Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol. Value in Health. 19(7). A545–A545. 1 indexed citations

Taylor, Peter C., E C Keystone, D. van der Heijde, et al.. (2015). Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study. Data Archiving and Networked Services (DANS). 67. 8–8. 15 indexed citations

Spindler, Alberto, Juan J. Gómez‐Reino, Edward J. Fudman, et al.. (2013). Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist. Data Archiving and Networked Services (DANS). 1 indexed citations

Dawes, Patrick, Aleksandar Dimić, Mark C. Genovese, et al.. (2013). Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs. Data Archiving and Networked Services (DANS). 65. 13 indexed citations

Weinblatt, M., Mark C. Genovese, M. Ho, et al.. (2013). Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate. Data Archiving and Networked Services (DANS). 65. 7 indexed citations

Weinblatt, M., Roy Fleischmann, T. Huizinga, et al.. (2012). Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Lara D. Veeken. 51(12). 2204–2214. 99 indexed citations

Weinblatt, M., R Fleischmann, Ronald van Vollenhoven, et al.. (2011). Efficacy and Safety of Certolizumab Pegol in a Broad Population of Patients with Active Rheumatoid Arthritis: Week 28 Results From a Phase IIIb Randomized Controlled Study. Data Archiving and Networked Services (DANS). 63(10). 2 indexed citations

10.

Keystone, Edward, D. van der Heijde, M. Weinblatt, et al.. (2011). Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial. Data Archiving and Networked Services (DANS). 63(10). 1 indexed citations

11.

Iannaccone, Christine, Jing Cui, Michelle Frits, et al.. (2010). Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Lara D. Veeken. 50(1). 40–46. 85 indexed citations

12.

Cui, Jing, et al.. (2009). Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Lara D. Veeken. 48(6). 613–617. 51 indexed citations

13.

Solomon, David H., Nicola Goodson, J.N. Katz, et al.. (2006). Patterns of cardiovascular risk in rheumatoid arthritis. Annals of the Rheumatic Diseases. 65(12). 1608–1612. 331 indexed citations

14.

Weinblatt, M.. (2004). Rheumatoid arthritis: more aggressive approach improves outlook.. Cleveland Clinic Journal of Medicine. 71(5). 409–413. 15 indexed citations

15.

Genovese, Mark C., Shira Cohen, D E Furst, et al.. (2001). Safety Of Combination Therapy With Anakinra And Etanercept In Patients With Rheumatoid Arthritis.. Arthritis & Rheumatism. 44(9). 23 indexed citations

16.

Weinblatt, M.. (1999). The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. British journal of rheumatology. 38(90001). 19–23. 50 indexed citations

17.

Weinblatt, M.. (1995). Efficacy of Methotrexate in Rheumatoid Arthritis. Lara D. Veeken. XXXIV(suppl 2). 43–48. 28 indexed citations

18.

Weinblatt, M., Simon M. Helfgott, Jonathan S. Coblyn, et al.. (1991). The effects of cyclosporin a on eicosanoid excretion in patients with rheumatoid arthritis. Arthritis & Rheumatism. 34(4). 481–485. 6 indexed citations

19.

Weinblatt, M.. (1989). Drug liberations With Non Steroidal Anti-Inflammatory Drugs (NSAIDs). Scandinavian Journal of Rheumatology. 18(sup83). 7–10. 21 indexed citations

20.

Spragg, J, Jonathan S. Coblyn, Patricia A. Fraser, K. Frank Austen, & M. Weinblatt. (1989). The Effect of Cyclosporine on Urinary Kallikrein Excretion in Patients with Rheumatoid Arthritis. Advances in experimental medicine and biology. 247A. 389–392. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact